Douglas Sterling Ross, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 17 | 2023 | 294 | 3.610 |
Why?
|
| Thyroid Neoplasms | 39 | 2023 | 2330 | 2.430 |
Why?
|
| Iodine Radioisotopes | 22 | 2023 | 1030 | 1.450 |
Why?
|
| Graves Disease | 7 | 2023 | 238 | 1.360 |
Why?
|
| Carcinoma, Papillary | 14 | 2016 | 785 | 1.180 |
Why?
|
| Thyroxine | 16 | 2021 | 665 | 1.170 |
Why?
|
| Thyroid Crisis | 3 | 2023 | 8 | 1.080 |
Why?
|
| Goiter | 4 | 2023 | 87 | 1.070 |
Why?
|
| Thyrotropin | 22 | 2021 | 833 | 1.010 |
Why?
|
| Hypothyroidism | 8 | 2021 | 668 | 0.920 |
Why?
|
| Iodine | 3 | 2023 | 285 | 0.890 |
Why?
|
| Thyrotoxicosis | 4 | 2016 | 85 | 0.840 |
Why?
|
| Thyroid Gland | 14 | 2018 | 1169 | 0.630 |
Why?
|
| Thyroid Nodule | 7 | 2020 | 763 | 0.620 |
Why?
|
| Adenocarcinoma, Follicular | 9 | 2022 | 323 | 0.560 |
Why?
|
| Thyroid Hormones | 10 | 2021 | 402 | 0.520 |
Why?
|
| Thyroidectomy | 10 | 2023 | 908 | 0.480 |
Why?
|
| Thyroid Diseases | 6 | 2020 | 386 | 0.450 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 3691 | 0.330 |
Why?
|
| Endocrinology | 4 | 2020 | 442 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2013 | 9278 | 0.270 |
Why?
|
| Antithyroid Agents | 4 | 2020 | 72 | 0.250 |
Why?
|
| Triiodothyronine | 5 | 1991 | 492 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 7 | 2020 | 7400 | 0.200 |
Why?
|
| Osteocalcin | 3 | 1998 | 274 | 0.190 |
Why?
|
| Thyroid Function Tests | 5 | 1991 | 288 | 0.160 |
Why?
|
| Thyroglobulin | 8 | 2013 | 111 | 0.160 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2020 | 339 | 0.150 |
Why?
|
| Trace Elements | 1 | 2019 | 193 | 0.150 |
Why?
|
| Models, Biological | 1 | 2013 | 9458 | 0.140 |
Why?
|
| China | 1 | 2023 | 2374 | 0.140 |
Why?
|
| Disease Outbreaks | 2 | 2006 | 1747 | 0.140 |
Why?
|
| Humans | 70 | 2024 | 761222 | 0.140 |
Why?
|
| Registries | 8 | 2020 | 8246 | 0.130 |
Why?
|
| Fever | 1 | 2024 | 1618 | 0.130 |
Why?
|
| Pituitary Gland | 4 | 2001 | 634 | 0.130 |
Why?
|
| Thyroiditis, Autoimmune | 2 | 2010 | 101 | 0.120 |
Why?
|
| Carcinoma | 4 | 2020 | 2330 | 0.110 |
Why?
|
| Radiopharmaceuticals | 1 | 2023 | 2684 | 0.110 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 236 | 0.110 |
Why?
|
| Medical Record Linkage | 1 | 2014 | 286 | 0.100 |
Why?
|
| Bone Density | 5 | 2000 | 3546 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2016 | 8519 | 0.100 |
Why?
|
| Thyroiditis | 1 | 1992 | 86 | 0.100 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2012 | 59 | 0.100 |
Why?
|
| Access to Information | 1 | 2014 | 316 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 1991 | 12747 | 0.090 |
Why?
|
| Gene Rearrangement | 1 | 2016 | 1125 | 0.090 |
Why?
|
| Bone Diseases | 1 | 1994 | 418 | 0.090 |
Why?
|
| Societies, Medical | 3 | 2020 | 3923 | 0.090 |
Why?
|
| Diphosphonates | 3 | 2000 | 634 | 0.080 |
Why?
|
| Female | 43 | 2020 | 392552 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 931 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2000 | 2046 | 0.070 |
Why?
|
| Aged | 19 | 2021 | 169292 | 0.070 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2013 | 1118 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2016 | 2426 | 0.070 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 1172 | 0.070 |
Why?
|
| Male | 33 | 2024 | 360703 | 0.070 |
Why?
|
| Self Report | 1 | 2018 | 3727 | 0.070 |
Why?
|
| Parathyroid Hormone | 2 | 1991 | 1803 | 0.070 |
Why?
|
| Bone and Bones | 2 | 1998 | 2568 | 0.060 |
Why?
|
| Quinazolines | 2 | 2013 | 1371 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2016 | 2220 | 0.060 |
Why?
|
| United States | 10 | 2020 | 72341 | 0.060 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 3453 | 0.060 |
Why?
|
| Bone Resorption | 2 | 2000 | 723 | 0.060 |
Why?
|
| Population Surveillance | 1 | 2016 | 2598 | 0.060 |
Why?
|
| Lung | 1 | 2024 | 9979 | 0.060 |
Why?
|
| Neoplasm Staging | 6 | 2016 | 11119 | 0.060 |
Why?
|
| Survival Analysis | 4 | 2012 | 10088 | 0.060 |
Why?
|
| Adult | 26 | 2024 | 221120 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 2119 | 0.060 |
Why?
|
| Ultrasonography | 6 | 2013 | 5969 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 1990 | 934 | 0.060 |
Why?
|
| Potassium Iodide | 1 | 1983 | 14 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 4513 | 0.060 |
Why?
|
| Thyroxine-Binding Proteins | 1 | 1983 | 24 | 0.050 |
Why?
|
| Bone Diseases, Metabolic | 1 | 1987 | 410 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2014 | 2515 | 0.050 |
Why?
|
| Middle Aged | 26 | 2020 | 220858 | 0.050 |
Why?
|
| Drug Resistance, Viral | 1 | 2008 | 862 | 0.050 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 58952 | 0.050 |
Why?
|
| Quality of Life | 6 | 2022 | 13367 | 0.050 |
Why?
|
| Biopsy, Needle | 3 | 1993 | 1624 | 0.050 |
Why?
|
| Radionuclide Imaging | 4 | 1999 | 1989 | 0.050 |
Why?
|
| Thyrotropin-Releasing Hormone | 1 | 2001 | 139 | 0.050 |
Why?
|
| Diet | 1 | 2019 | 8048 | 0.050 |
Why?
|
| Hepatitis | 1 | 1983 | 228 | 0.050 |
Why?
|
| England | 1 | 2002 | 526 | 0.050 |
Why?
|
| Delivery of Health Care | 2 | 2016 | 5333 | 0.040 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2001 | 199 | 0.040 |
Why?
|
| Osteitis Fibrosa Cystica | 1 | 2000 | 11 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15841 | 0.040 |
Why?
|
| Age Factors | 3 | 2015 | 18384 | 0.040 |
Why?
|
| Periodicity | 1 | 2001 | 347 | 0.040 |
Why?
|
| Methimazole | 1 | 2019 | 41 | 0.040 |
Why?
|
| Propylthiouracil | 1 | 2019 | 68 | 0.040 |
Why?
|
| Iodide Peroxidase | 1 | 2001 | 294 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2015 | 7965 | 0.040 |
Why?
|
| Testosterone | 1 | 1990 | 2472 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 4909 | 0.040 |
Why?
|
| Luminescent Measurements | 2 | 1990 | 340 | 0.040 |
Why?
|
| Thyroiditis, Subacute | 1 | 1998 | 11 | 0.040 |
Why?
|
| Prognosis | 4 | 2015 | 29688 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2014 | 4822 | 0.030 |
Why?
|
| Bone Remodeling | 1 | 2000 | 583 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 2 | 2022 | 5493 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2020 | 454 | 0.030 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 2913 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 2019 | 578 | 0.030 |
Why?
|
| Antineoplastic Agents | 3 | 2008 | 13632 | 0.030 |
Why?
|
| Japan | 1 | 2019 | 1378 | 0.030 |
Why?
|
| Calcitonin | 2 | 2013 | 329 | 0.030 |
Why?
|
| Menopause | 2 | 2012 | 1646 | 0.030 |
Why?
|
| Professional Competence | 1 | 2018 | 430 | 0.030 |
Why?
|
| Collagen | 2 | 2000 | 2635 | 0.030 |
Why?
|
| Depression, Chemical | 2 | 1998 | 184 | 0.030 |
Why?
|
| Adenoma | 1 | 1984 | 2159 | 0.030 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 39127 | 0.030 |
Why?
|
| Carcinoma, Medullary | 2 | 2008 | 115 | 0.030 |
Why?
|
| Retrospective Studies | 8 | 2022 | 80675 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2015 | 6819 | 0.030 |
Why?
|
| Drug Approval | 1 | 2020 | 812 | 0.030 |
Why?
|
| Time Factors | 6 | 2012 | 39957 | 0.030 |
Why?
|
| Perioperative Period | 1 | 2014 | 252 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 336 | 0.030 |
Why?
|
| Health Status | 1 | 2006 | 4077 | 0.030 |
Why?
|
| Hormone Replacement Therapy | 1 | 2018 | 751 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2008 | 4527 | 0.020 |
Why?
|
| Sodium Pertechnetate Tc 99m | 1 | 1991 | 54 | 0.020 |
Why?
|
| Adolescent | 6 | 2011 | 88300 | 0.020 |
Why?
|
| Treatment Outcome | 7 | 2016 | 64681 | 0.020 |
Why?
|
| Syndrome | 1 | 1998 | 3271 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2013 | 3461 | 0.020 |
Why?
|
| Neck | 2 | 2013 | 734 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2014 | 365 | 0.020 |
Why?
|
| Immunoglobulins, Thyroid-Stimulating | 1 | 2011 | 34 | 0.020 |
Why?
|
| Receptors, Thyrotropin | 1 | 2011 | 45 | 0.020 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 320 | 0.020 |
Why?
|
| Fatigue | 1 | 2018 | 1550 | 0.020 |
Why?
|
| Consensus | 1 | 2020 | 3134 | 0.020 |
Why?
|
| Peptides | 2 | 2000 | 4353 | 0.020 |
Why?
|
| HIV-1 | 1 | 2008 | 6851 | 0.020 |
Why?
|
| Glycoprotein Hormones, alpha Subunit | 1 | 1990 | 95 | 0.020 |
Why?
|
| Affect | 1 | 2018 | 1486 | 0.020 |
Why?
|
| Recombinant Proteins | 4 | 2006 | 6504 | 0.020 |
Why?
|
| Rats | 3 | 1991 | 23705 | 0.020 |
Why?
|
| Diagnosis, Differential | 3 | 2013 | 12976 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2020 | 11512 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 1991 | 1545 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2019 | 2159 | 0.020 |
Why?
|
| Neck Dissection | 1 | 2011 | 201 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 664 | 0.020 |
Why?
|
| Incidence | 2 | 2020 | 21366 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 1990 | 573 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1990 | 239 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 1989 | 862 | 0.020 |
Why?
|
| Gonadotropins | 1 | 1990 | 241 | 0.020 |
Why?
|
| Age of Onset | 1 | 2015 | 3307 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2012 | 489 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2014 | 1385 | 0.020 |
Why?
|
| Orchiectomy | 1 | 1990 | 463 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4107 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2009 | 42225 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 1993 | 1738 | 0.020 |
Why?
|
| Health Policy | 1 | 2020 | 2679 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2012 | 2277 | 0.020 |
Why?
|
| Prospective Studies | 6 | 2012 | 54437 | 0.020 |
Why?
|
| Immunoassay | 1 | 1990 | 743 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 1506 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2008 | 148 | 0.020 |
Why?
|
| Research | 1 | 2015 | 1976 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 3418 | 0.020 |
Why?
|
| Age Distribution | 1 | 2012 | 2871 | 0.020 |
Why?
|
| Emotions | 1 | 2018 | 2742 | 0.020 |
Why?
|
| Collagen Type I | 2 | 2000 | 616 | 0.020 |
Why?
|
| Internet | 1 | 2018 | 3096 | 0.020 |
Why?
|
| Child | 3 | 2011 | 80154 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 1500 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2011 | 1241 | 0.020 |
Why?
|
| Femur | 1 | 1991 | 1308 | 0.020 |
Why?
|
| Fibrosis | 1 | 1992 | 2052 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2010 | 1270 | 0.010 |
Why?
|
| Postmenopause | 1 | 1993 | 2514 | 0.010 |
Why?
|
| Longevity | 1 | 2012 | 1063 | 0.010 |
Why?
|
| Piperidines | 1 | 2013 | 1656 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 1737 | 0.010 |
Why?
|
| Cohort Studies | 3 | 2012 | 41496 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 4014 | 0.010 |
Why?
|
| South Africa | 1 | 2008 | 1843 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1990 | 2203 | 0.010 |
Why?
|
| Kinetics | 1 | 1990 | 6312 | 0.010 |
Why?
|
| HIV Infections | 1 | 2008 | 17348 | 0.010 |
Why?
|
| Animals | 4 | 2020 | 168089 | 0.010 |
Why?
|
| Young Adult | 3 | 2016 | 59222 | 0.010 |
Why?
|
| Cognition | 1 | 2018 | 6988 | 0.010 |
Why?
|
| Physicians | 1 | 2018 | 4584 | 0.010 |
Why?
|
| Radiography | 2 | 2006 | 6974 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2008 | 2839 | 0.010 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2008 | 1895 | 0.010 |
Why?
|
| Risk Factors | 1 | 2006 | 74241 | 0.010 |
Why?
|
| Pregnancy | 2 | 2011 | 29893 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2008 | 2567 | 0.010 |
Why?
|
| Quality of Health Care | 1 | 2014 | 4321 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 26072 | 0.010 |
Why?
|
| Sex Factors | 1 | 2012 | 10553 | 0.010 |
Why?
|
| Depression | 1 | 2018 | 8132 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 12474 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 6486 | 0.010 |
Why?
|
| Gene Expression | 1 | 1990 | 7571 | 0.010 |
Why?
|
| Osteolysis | 1 | 1998 | 274 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1988 | 10756 | 0.010 |
Why?
|
| Calcium | 1 | 1989 | 5719 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2010 | 9319 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 859 | 0.010 |
Why?
|
| Risk | 1 | 2006 | 9616 | 0.010 |
Why?
|
| Double-Blind Method | 2 | 1998 | 12341 | 0.010 |
Why?
|
| Genotype | 1 | 2008 | 12985 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 2217 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1983 | 6304 | 0.010 |
Why?
|
| Creatinine | 1 | 1998 | 1897 | 0.010 |
Why?
|
| Amino Acids | 1 | 1998 | 1703 | 0.010 |
Why?
|
| Acute Disease | 1 | 1983 | 7226 | 0.010 |
Why?
|
| Fasting | 1 | 1998 | 1603 | 0.010 |
Why?
|
| Pain | 1 | 2006 | 5072 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 1997 | 14675 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 4851 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2000 | 1812 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1998 | 6223 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 20588 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 26200 | 0.000 |
Why?
|
| Infant | 1 | 2009 | 36170 | 0.000 |
Why?
|
| Survival Rate | 1 | 1998 | 12728 | 0.000 |
Why?
|
| Mice | 1 | 1990 | 81330 | 0.000 |
Why?
|
| Adenocarcinoma | 1 | 1993 | 6341 | 0.000 |
Why?
|